Market Cap (In USD)
144.95 Million
Revenue (In USD)
-
Net Income (In USD)
-60.36 Million
Avg. Volume
484.7 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.0-6.35
- PE
- -
- EPS
- -
- Beta Value
- 0.135
- ISIN
- KYG9TY5A1016
- CUSIP
- -
- CIK
- 1855644
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Robert Lisicki
- Employee Count
- -
- Website
- https://zurabio.com
- Ipo Date
- 2023-03-21
- Details
- Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
More Stocks
-
2281Tanmiah Food Company
2281
-
WNWDWindward Ltd.
WNWD
-
DMI
-
XTPT
-
8061Seika Corporation
8061
-
ASN
-
ESGREnstar Group Limited
ESGR
-
000068